defeatHIV Investigators

We have assembled a powerful team comprising some of the world’s leaders in HIV virology, transplantation biology, genome modification, and gene transfer, with the goal of developing innovative approaches toward the cure of established HIV infection.

Keith JeromeKeith R. Jerome, MD, PhD

Associate Member
Vaccine and Infectious Disease Division
Clinical Research Division
Fred Hutchinson Cancer Research Center
Professor and Head, Virology Division
Department of Laboratory Medicine,
University of Washington
Projects and Cores | Project 4 | Core E


+Bio

Dr. Keith Jerome’s laboratory has considerable experience in the study of chronic and latent viral infections, and the mechanisms by which these viruses evade the host immune response.  More recently they have sought to apply newer technologies, such as homing endonucleases, to eliminate persistent reservoirs of viruses such as HIV, hepatitis B virus, and herpes simplex virus.  In addition to his basic science background, Dr. Jerome is also Head of the UW Virology Division and Director of the UW Molecular Virology Laboratory, which performs >45,000 diagnostic virology tests each year, and >100,000 research assays. He currently serves as PI for the Laboratory Core of the Hepatitis B Research Network, developing and coordinating testing and result reporting for 28 sites throughout the US and Canada.

Hans-Peter Kiem, MDHans-Peter Kiem, MD

Member
Clinical Research Division
José Carreras / E. Donnall Thomas Endowed Chair for Cancer Research
Fred Hutchinson Cancer Research Center
Professor of Medicine / Oncology
Adjunct Professor of Pathology
University of Washington School of Medicine
Projects and Cores | Project 3 | Core B


+Bio

Dr. Hans-Peter Kiem has more than 20 years of experience with hematopoietic cell transplantation and more than 15 years of experience with gene transfer and gene therapy studies. Dr. Kiem is Director of the preclinical and clinical vector program and thus has extensive experience in the generation and production of most viral and nonviral gene transfer techniques. A significant focus of Dr. Kiem’s lab is to use gene transfer technology to study hematopoietic stem cell biology and more recently also induced pluripotent stem cells (iPSCs). They study stem cell biology and gene transfer technologies in small and large animal models to facilitate the translation to clinical applications, with the goal of developing novel stem cell-based treatment strategies for patients with genetic, infectious and malignant diseases. Dr. Kiem currently has 2 clinical protocols to study the use of gene-modified hematopoietic stem cells in patients.


Dr. Roger BumgarnerRoger Bumgarner, PhD
Associate Professor
Department of Microbiology, University of Washington
Projects and Cores | Core C

+Bio

Dr. Roger Bumgarner’s Ph.D. training was in chemical physics and in that realm he constructed complex spectrometers and solved quantum mechanics problems.  Dr. Bumgarner later trained in Dr. Leroy Hood’s laboratory where he worked on new sequencing and genotyping technologies, ran his high throughput sequencing group, established both macro and microarray facilities and developed algorithms and software for processing a wide variety of genomics data.  Dr. Bumgarner remains deeply connected to both technology and software development and recently co-authored work on the construction and validation of Bayesian networks in yeast.


Paula CannonPaula Cannon, PhD
Associate Professor
Molecular Microbiology & Immunology, Pediatrics,
Biochemistry & Molecular Biology
Keck School of Medicine
University of Southern California
Projects and Cores | Supplemental



Stephen DeRosaStephen C. De Rosa, MD
Associate Member
Vaccine and Infectious Disease Division
Fred Hutchinson Cancer Research Center
Research Associate Professor
Department of Laboratory Medicine
University of Washington
Projects and Cores | Core D

+Bio
Dr. Stephen De Rosa has extensive experience examining T cell functions at the single cell level using advanced flow cytometric techniques.  This includes examination of T-cell responses specific to viral infections including CMV, EBV, HIV and Hepatitis B.  Since 2004, Dr. De Rosa’s research has focused more intensely on examining antigen-specific T-cell responses to HIV infection or vaccination, while working with the HIV Vaccine Trials Network (HVTN) on the development of new assays to evaluate vaccine immunogenicity and ultimately vaccine efficacy.  Dr. De Rosa has developed assays that examine multiple T cell markers and functions simultaneously while integrating new technologies into his vaccine assessments as they become available.


Philip GregoryPhilip D. Gregory, PhD
Chief Scientific Officer and Vice President for Research
Sangamo BioSciences, Inc
Projects and Cores | Project 2

+Bio

Dr. Gregory has over a decade of experience in the design and deployment of engineered zinc finger nucleases (ZFNs), from proof of concept research through early phase clinical trials. Under his direction SB-728-T—a CCR5-specific ZFN modified CD4+ T-cell product for the potential treatment of HIV—has now entered the clinic. More recently, his group has pioneered the application of ZFNs to stem cells for the purposes of gene disruption or targeted gene addition. Dr. Gregory brings to the collaboratory an extensive track record of managing multicenter research programs to success.


Michael HolmesMichael C. Holmes, PhD
Senior Director of Therapeutic Gene Modification
Sangamo BioSciences, Inc
Projects and Cores | Project 2

+Bio

Dr. Michael Holmes has successfully managed two separate ZFN development projects that have advanced to clinical trials: a project with City of Hope to generate glucocorticoid-resistant CTLs via ZFN-mediated disruption of the glucocorticoid receptor gene to selectively target glioma cells in patients with glioblastoma multiforme; and a project with the University of Pennsylvania to generate and reinfuse autologous CD4 T-cells from HIV patients that were modified ex vivo to disrupt the CCR5 gene. Dr. Holmes has extensive experience in basic science research and have been involved in numerous publications describing the application of ZFNs to modify human cells, including the use of ZFNs to protect cells from HIV infection.


Shiu-Lok Hu, PhDShiu-Lok Hu, PhD
Professor
Department of Pharmaceutics, University of Washington
Projects and Cores | Core A

+Bio

Dr. Shiu-Lok Hu developed the first recombinant live virus vector as a candidate vaccine against HIV-1 and provided the first demonstration of protection against SIV infection in a macaque model by the “poxvirus prime-protein boost” immunization strategy. He joined the faculty at the University of Washington, Seattle, in 1997. He is currently the Milo Gibaldi Endowed Professor of Pharmaceutics and Head of the AIDS-Related Research Core at the Washington National Primate Research Center. His research focuses on HIV vaccine, host resistance against retrovirus infection and therapy against AIDS.


Dr. Jim MullinsJames I. Mullins, PhD
Professor
Departments of Medicine and Microbiology
University of Washington
Projects and Cores | Core C

+Bio

Dr. James Mullins has been involved in the genetic analysis of retroviruses since 1978 and has worked in the AIDS research field since 1982. Dr. Mullins’ lab has been involved in the analysis of retrovirus phylogenetics and genetic diversification within and between hosts for the past 33+ years. He has served on expert panels from the NIH, WHO and UNAIDS program for the analysis of HIV molecular epidemiology and currently serve as PI of the Seattle Primary HIV Infection Program. His lab has made several important contributions to the understanding of AIDS, pioneered numerous laboratory tools of widespread use in molecular biology and HIV research, and developed many web-based and stand alone computational tools for HIV genetic research.


John J. Rossi, PhDJohn J. Rossi, PhD
Lidow Family Chair and Professor
Molecular and Cellular Biology
Morgan and Helen Chu Dean
Irell & Manella Graduate School of Biological Sciences
Beckman Research Institute of the City of Hope
Projects and Cores | Project 5

+Bio
For the past decade, Dr. John Rossi’s laboratory has been exploring mechanisms for delivery of RNA based therapeutics to hematopoietic cells. Dr. Rossi has extensive experience using lentiviral vectors for gene expression and RNA aptamers for targeted systemic delivery of small RNAs. His lab has recently been using G5 PAMAM dendrimers to deliver therapeutic RNAs to T-cells in vitro and in vivo.  Dr. Rossi’s current efforts are directed at using aptamers and other nanoparticles to deliver Zn finger and homing endonuclease encoding mRNAs to hematopoietic progenitors and lymphocytes to trigger site specific genome modifications.


Andrew M. Scharenberg, MDAndrew M. Scharenberg, MD
Professor
Department of Pediatrics, Seattle Children’s Hospital
Adjunct Professor
Department of Immunology, University of Washington
Projects and Cores | Project 4

+Bio

Dr. Andrew Scharenberg’s laboratory has spent the last six years working on homing endonuclease engineering and DNA double strand break repair. This work led to Dr. Scharenberg’s present role as principal investigator for the NIH-roadmap funded Northwest Genome Engineering Consortium (NGEC), a group of seven laboratories in the Seattle area working on developing tools for genome engineering. Over the past three years, their consortium has developed an advanced platform for engineering homing endonucleases to cleave novel target sites, utilizing an approach that combines modular assembly, computational modeling and either bacterial or yeast selection systems. They have also developed accessory approaches for manipulating how homing endonuclease-induced DNA breaks are resolved to efficiently generate desired genome engineering outcomes.


Ann E. Woolfrey, MDAnn E. Woolfrey, MD
Associate Member
Clinical Research Division
Fred Hutchinson Cancer Research Center
Professor
Department of Pediatrics, University of Washington
Projects and Cores | Project 1

+Bio

Dr. Ann Woolfrey has led more than 20 clinical protocols at FHCRC, primarily aimed at improving outcome after HCT for treatment of nonmalignant disorders.  In 2010, Dr. Woolfrey helped establish the FHCRC/Harborview Hospital as a primary site in the AIDS Malignancy Consortium (AMC), and is currently principal investigator of 2 active protocols studying HCT in patients with HIV.  In addition, she is Medical Director of the Unrelated Donor (URD) Program at the FHCRC/Seattle Cancer Care Alliance – one of the largest URD programs in the world.  Dr. Woolfrey collaborates with laboratory investigators in a number of areas, including improving transplant outcomes, performing multi-center pilot studies and for retrospective analyses of registry data.